



SUPRIYA LIFESCIENCE LTD.
Creating true values that bind global health

Date: May 29, 2024

To,
BSE Limited
Phiroze Jeejeebhoy Towers
Dalal Street,
Mumbai – 400 001
Scrip Code: 543434

To,
National Stock Exchange of India Limited
Exchange Plaza, C-1, Block G
Bandra Kurla Complex
Bandra (E), Mumbai – 400 051
Scrip Symbol: SUPRIYA

Dear Sir/Madam,

Subject: Press Release- Audited Financial Results for the quarter and year ended March 31, 2024

The Board of Directors of the Company at their Meeting held on May 28, 2024 has inter alia, considered and approved the Audited Financial Results for the quarter and year ended March 31, 2024.

Please find attached the Press Release with regard to the Audited Financial Results of the Company for the quarter and year ended March 31, 2024.

Kindly take the same on record and acknowledge the receipt.

Thanking you,

For Supriya Lifescience Limited

Shweta Singh
Company Secretary & Compliance Officer
Membership No.: A44973

Corporate office : 207/208, Udyog Bhavan, Sonawala Road, Goregaon (East), Mumbai – 400 063. Maharashtra, India.
Tel: +91 22 40332727 / 66942507 Fax : +91 22 26860011 GSTIN: 27AALCS8686A1ZX
CIN: L51900MH2008PLC180452 E-mail: supriya@supriyalifescience.com Website: www.supriyalifescience.com

Factory : A-5/2, Lote Parshuram Industrial Area, M.I.D.C. Tal.– Khed, Dist. – Ratnagiri, Pin :415 722, Maharashtra, India.
Tel: +91 2356 272299 Fax: +91 2356 272178 E-mail: factory@supriyalifescience.com

GOVT. RECOGNISED EXPORT HOUSE



SUPRIYA LIFESCIENCE LTD.

Press Release for immediate distribution

Supriya Lifescience Ltd. Unveils Remarkable PAT Growth of 32% in FY24, Amidst 23.7% Revenue Surge

Mumbai, 28th May 2024: The unaudited financial statements for the fourth quarter of FY24 have been released by Supriya Lifescience Ltd., a cGMP-compliant business with a strong track record in API manufacturing and a focus on products from a variety of therapeutic segments, including anti-histamine, anti-allergic, vitamin, anaesthetic, and anti-asthmatic.

Key Consolidated Financial Highlights:

Particulars	FY24	FY23
Revenues (in Rs Cr)	570.37	460.94
Gross Profit (in Rs Cr)	348.63	280.13
EBITDA (in Rs Cr)	172.97	128.90
PAT (in RsCr)	119.11	89.86
PAT Margin	20.9%	19.5%
Full Year EPS (in Rs)	14.80	11.16

Key Highlights for FY24:

In FY24, Supriya Lifescience Ltd. witnessed remarkable growth in its revenue, reporting a 23.7% year-over-year increase, reaching Rs. 570.37 crores compared to Rs. 460.94 crores in FY23.

Gross Profit for FY24 stood at Rs. 348.63 crores, with a growth of 24.5% compared to Rs. 280.13 crores in FY23.

EBITDA for FY24 increased by 34.2% YoY to Rs. 172.97 crores, with an EBITDA Margin of 30.3%, as opposed to an EBITDA of Rs. 128.90 crores in FY23 with an EBITDA margin of 28.0%.

The Profit After Tax (PAT) for FY24 at Rs 119.11 crore, compared to Rs 89.86 crore in FY23 an increase of 32.6%.

The PAT Margin improved from 19.5% in FY23 to 20.9% in FY24.

The company's business in Europe picked up this year, contributing 41% to the net revenue, compared to last year which stood at 33%. This led to a more balanced revenue distribution across regions.

The Analgesic and Anaesthetic segment led the revenue growth and contributed to 46% of sales in FY24, compared to 44% last year. Vitamin segment also performed well contributing 13% compared to 11% last year. The contribution of the Anit-histamine segment remains robust at 15% of sales.

Key Consolidated Financial Highlights:

Particulars	Q4 FY24	Q4 FY23
Revenues (in Rs Cr)	158.18	142.27
Gross Profit (in Rs Cr)	99.91	94.71
EBITDA (in Rs Cr)	55.50	55.05
PAT (in RsCr)	36.40	38.23
PAT Margin	23.0%	26.9%
Quarterly EPS (in Rs)	4.52	4.75

Key Highlights for Q4 FY24:

In the fourth quarter of FY24, Supriya Lifescience Ltd. witnessed remarkable growth in its revenue, reporting an 11.2 % year-over-year increase, reaching Rs. 158.18 crore compared to Rs. 142.27 crore in Q4 FY23.

Gross Profit for Q4 FY24 stood at Rs. 99.91 crore, with a growth of 5.5% compared to Rs. 94.71 crore in Q4 FY23.

EBITDA for Q4 FY24 stood at Rs. 55.50 crore, with an EBITDA Margin of 35.1%, as opposed to an EBITDA of Rs. 55.05 crore in Q4 FY23 with an EBITDA margin of 38.7%. This marks a growth of 0.8% YoY.

The Profit After Tax (PAT) for Q4 FY24 at Rs 36.40 crore, compared to Rs 38.23 crore in Q4 FY23.

The PAT Margin stood at 23.0% in Q4 FY24, compared to 26.9% in Q4 FY23.

Mr. Satish Wagh, Chairman and Managing Director, Supriya Lifescience Ltd, commenting on the results, said, *“Our unwavering commitment to quality, innovation, and strategic expansion has driven another year of remarkable growth. As we navigate through evolving landscapes, Supriya Lifescience remains steadfast in our mission to deliver excellence, enrich lives, and shape the future of healthcare.”*

.....

Disclaimer Statements in this “Document” describing the company’s objectives, projections, estimates, expectations, plans or predictions, or industry conditions or events may be “forward-looking statements” within the meaning of applicable securities laws and regulations. Actual results, performance, or achievements could differ materially from those expressed or implied. The Company undertakes no obligation to update or revise forward-looking statements to reflect developments or circumstances that arise or to reflect the occurrence of unanticipated developments or circumstances after the date hereof.

About Supriya Lifescience Ltd.:

Supriya Lifescience Ltd., a world-renowned producer of active pharmaceutical ingredients, was founded in 1987. Our cutting-edge facility has certifications from Health Canada, EUGMP, EDQM, USFDA, and NMPA. The company is headquartered in Mumbai, India, and our facility is located in Khed, District Ratnagiri. Our globally compliant facilities (EMA, US FDA, WHO, PMDA, TGA, KFDA, ANVISA) are supported by robust R&D, eight active CEPs, and fourteen active USDMFs. EHS requirements and ethical principles guide our core business. The company's primary focus is to build intermediates and APIs for innovators and generic firms. We also exclusively collaborate with partners in the capacity of CMOs.

For more details, contact:

Abhishek Chawande: Abhishek.Chawande@dentsu.com | 9664516774

Ashna Malpe: ashna.malpe@dentsu.com | 8850213268